Brookstone Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Brookstone Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-259	Closed	-$200K	–	1254
2025 Q4	$200K	Buy	+259	New	+$176K	﹤0.01%	1134
2021 Q3	–	Sell	-429	Closed	-$248K	–	776
2021 Q2	$248K	Buy	+429	New	+$217K	﹤0.01%	633
2020 Q3	–	Sell	-1,897	Closed	-$1.18M	–	466
2020 Q2	$1.18M	Buy	+1,897	New	+$1.08M	0.07%	157
2015 Q4	–	Sell	-29	Closed	-$13K	–	714
2015 Q3	$13K	Hold	29	–	–	﹤0.01%	990
2015 Q2	$15K	Buy	+29	New	+$14.2K	﹤0.01%	1006

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Brookstone Capital Management's REGN Position: Q1 2026 in Review

Brookstone Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 259 shares — an estimated $200K sold.

Brookstone Capital Management first reported a position in REGN in Q2 2015 and held it in 5 quarters. The position peaked at $1.18M in Q2 2020. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Brookstone Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Brookstone Capital Management sold 259 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $200K.
Brookstone Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Brookstone Capital Management's Regeneron Pharmaceuticals position peaked at $1.18M in Q2 2020.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Brookstone Capital Management's 13F filing for Q1 2026, filed 16 Apr 2026.